RADIUS HEALTH, INC. (NASDAQ:RDUS) Files An 8-K Results of Operations and Financial Condition

On November 1, 2018, Radius Health, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2018. A copy of the press release is attached hereto as Exhibit 99.1.

The information contained in this Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly provided by specific reference in such a filing.

(d) Exhibits

Radius Health, Inc. ExhibitEX-99.1 2 rdus-ex991_7.htm EX-99.1 rdus-ex991_7.htm Exhibit 99.1   Radius Health Announces Third Quarter 2018 Operating Results and Financial Guidance for FY 2018 and FY 2019 TYMLOS® U.S. net sales continued to increase in the third quarter of 2018,…To view the full exhibit click here
About RADIUS HEALTH, INC. (NASDAQ:RDUS)
Radius Health, Inc. is a biopharmaceutical company focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Its product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis. Its clinical pipeline also includes an investigational abaloparatide transdermal patch for use in osteoporosis and the investigational drug RAD1901 for use in hormone-driven and hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for use in cancer.